Search for: "Allergan, Inc. v. Apotex Inc" Results 1 - 20 of 26
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Sep 2014, 9:41 pm by Patent Docs
Allergan had asserted its 7,351,404 patent (the '404 patent) and Duke asserted its 7,388,029 patent (the '029 patent) after Apotex filed an ANDA for a generic version of Allergan's Latisse®, an ophthalmic solution comprising bimatoprost (a prostaglandin F-2-alpha ("PGF") analog) as the active ingredient. [read post]
7 Apr 2014, 9:59 pm by Patent Docs
The case involved patentee Senju Pharmaceutical's (joined by Kyorin Pharmaceutical Co. and Allergan, Inc.) suit against Apotex in response to a Paragraph IV certification against Senju's patented ocular antimicrobial agent containing the drug Gatifloxacin as claimed in U.S. [read post]
28 May 2007, 7:03 pm
Allergan Inc. v. [read post]
19 Apr 2015, 9:56 pm by Patent Docs
Apotex Inc. et al. 1:15-cv-02676; filed April 15, 2015... [read post]
21 Mar 2015, 6:26 am by Lawrence B. Ebert
Reference IPR2015-00858.Although  this claim survived litigation challenge in Allergan, Inc. v. [read post]
19 May 2011, 9:24 pm by Lawrence B. Ebert
Unlike Apotex, Exela appeals the district court’s finding that the product pro- posed in its ANDA infringes Allergan’s patent rights. [read post]
9 Nov 2017, 4:00 am by Alan Macek
In that decision (Apotex Inc. v. [read post]
21 Nov 2014, 4:00 am by Paula Bremner
As would be expected, Apotex (generic2) successfully requested that at least a portion of Allergan’s court materials in case1 be filed publicly, prior to the filing of Apotex’s factum. [read post]
8 Jul 2016, 4:00 am by Alan Macek
Apotex Inc., 2016 FC 344 at para 13). [read post]